home / stock / arav / arav news

ARAV News and Press, Aravive Inc. From 07/28/23

Stock Information
Company Name: Aravive Inc.
Stock Symbol: ARAV
Market: NASDAQ
Website: aravive.com
Menu
ARAV ARAV Quote ARAV Short ARAV News ARAV Articles ARAV Message Board
Get ARAV Alerts

News, Short Squeeze, Breakout and More Instantly...
ARAV - Catalyst watch: Amazon earnings, jobs report and will Apple talk AI?

2023-07-28 14:00:40 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
ARAV - Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European S...

ARAV - WW, HRTX and WAL are among pre market gainers

2023-07-26 08:28:03 ET Silicon Motion Technology  ( NASDAQ: SIMO ) +80% . PacWest Bancorp ( PACW ) +30% . Warrantee Inc. American Depositary  ( WRNT ) +24% . Tilray Brands ( TLRY ) +13% spikes as bottom line improves amid Q4 revenue ...

ARAV - Aravive to Participate in William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023

HOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer will be participa...
ARAV - Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)

HOUSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that in accordance with Nasdaq rules regarding employment inducement awards, t...

ARAV - Aravive To Participate in the Jefferies Global Healthcare Conference

HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, ...

ARAV - Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023

HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 2 trial of batiraxce...
ARAV - Aravive: Very Small Company With Late Stage Trial In Ovarian Cancer

2023-05-24 08:52:11 ET Summary Batiraxcept targets a slightly larger market than ImmunoGen's mirvetuximab. It has no ocular toxicities so far, and a generally benign tox profile. However, mirve is the clear winner now with superior confirmatory data. I was recently asked...

ARAV - Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

Trial initiation anticipated in 2H 2023 with topline data anticipated in 2H 2025 Updated Phase 1b/2 ccRCC data to be presented at ASCO 2023 HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company de...

ARAV - Aravive GAAP EPS of -$0.66 misses by $0.34, revenue of $1.49M beats by $1.07M

2023-05-10 17:23:02 ET Aravive press release ( NASDAQ: ARAV ): Q1 GAAP EPS of -$0.66 misses by $0.34 . Revenue of $1.49M (+36.7% Y/Y) beats by $1.07M . For further details see: Aravive GAAP EPS of -$0.66 misses by $0.34, revenue of $1.49M beats by $1.07M
Previous 10 Next 10